COVID-19-associated acute kidney injury: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Main|COVID-19}} | {{Main|COVID-19}} | ||
{{CMG}}; {{AE}} {{S.G.}}, {{NN}} | {{CMG}}; {{AE}} {{S.G.}}, {{NN}} | ||
Revision as of 16:38, 25 June 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2], Nasrin Nikravangolsefid, MD-MPH [3]
Synonyms and keywords: COVID-19-associated AKI
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating COVID-19-Associated Acute Kidney Injury From Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Evaluation Guide of Elevated Biomarkers | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies